Drug Trial Radar · NCT07818759
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Jan 18, 2027
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- NeuroGTIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if one infusion of rAAV9-CMV-hNAGLUop can treat patients with Sanfilippo syndrome (MPS III) 6 months or older. The main questions it aims to answer are: * Is the treatment safe? * Is there a change in enzyme activities,? * Is there a change in natural history trajectory of motor, language, feeding, adaptive and cognitive function? Participants will be asked to come to Washington University St. Louis and stay in the hospital overnight following the infusion. Partcipant and caregiver(s) will be asked to stay near the hospital for the first month and come back periodically for clinic visits.
Conditions
- Sanfilippo Syndrome (MPS III)
Interventions
rAAV9-CMV-hNAGLUopBiological
Systemic rAAV9-CMV-hNAGLUop gene delivery given once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of SafetyTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine Division of Genetics and Genomic Medicine, Rare Diseases Department of Pediatrics
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.